Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. J Diabetes Investig. 2021 Jan;12(1):74-81. doi: 10.1111/jdi.13318. Epub 2020 Jul 10. J Diabetes Investig. 2021. PMID: 32506833 Free PMC article.
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K, Toyoda M, Hatori N, Saito N, Kanaoka T, Sakai H, Furuki T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Diabetes Technol Ther. 2021 Feb;23(2):110-119. doi: 10.1089/dia.2020.0165. Epub 2020 Aug 13. Diabetes Technol Ther. 2021. PMID: 32721227
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.
Furuki T, Kobayashi K, Toyoda M, Hatori N, Sakai H, Sato K, Miyakawa M, Tamura K, Kanamori A. Furuki T, et al. Among authors: kobayashi k. J Clin Hypertens (Greenwich). 2020 Dec;22(12):2306-2314. doi: 10.1111/jch.14084. Epub 2020 Oct 21. J Clin Hypertens (Greenwich). 2020. PMID: 33086437 Free PMC article.
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. J Diabetes Investig. 2021 Aug;12(8):1408-1416. doi: 10.1111/jdi.13491. Epub 2021 Feb 1. J Diabetes Investig. 2021. PMID: 33377605 Free PMC article.
Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
Kawai Y, Uneda K, Yamada T, Kinguchi S, Kobayashi K, Azushima K, Kanaoka T, Toya Y, Wakui H, Tamura K. Kawai Y, et al. Among authors: kobayashi k. Diabetes Res Clin Pract. 2022 Jan;183:109146. doi: 10.1016/j.diabres.2021.109146. Epub 2021 Nov 12. Diabetes Res Clin Pract. 2022. PMID: 34780865
11,769 results
You have reached the last available page of results. Please see the User Guide for more information.